Randomized Phase II Study of Dose-Dense Fluorouracil Plus Epirubicin75 Plus Cyclophosphamide (FEC75) and Fluorouracil Plus Epirubicin90 Plus Cyclophosphamide (FEC90) as Adjuvant Therapy for Early Breast Cancer

Registry ID

EUCTR2004-000806-39

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

CECOG

Start date

2005-02-10

Completion date

2006-12-04

Last update

2026-08-16

Conditions

• Early Breast Cancer

Summary

The primary objective of this randomized phase II study is to determine the relative dose intensity (RDI) of 6 (six) adjuvant cycles of FEC75 and FEC90 regimens given every 14 days with pegfilgrastim (Neulasta) support in subjects with early breast cancer.

Locations

• , , Hungary
• , , Slovakia

Related clinical trials

• Optimising Adjuvant Chemotherapy Prescription in Young Patients With Hormone-dependent Breast Cancer Using Genomic Tests
• A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)
• Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
• Refusal of Sentinel Lymph Node Biopsy in Patients With Luminal A Subtype Early Breast Cancer
• Adherence to Aromatase Inhibitors ± Abemaciclib Treatment in Patients With Early-stage HER2-negative Breast Cancer
• Evaluation of the Effectiveness of Managing Chemotherapy Side Effects Using ePRO and a Standardized Telenursing Program for Cancer Patients

View on source registry